Cookie Settings
 
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

LIVIAL® (2.5 mg tibolone): an option for postmenopausal women1

After a woman’s last menstruation, a sharp decline in oestrogen plasma levels occurs, leading to a variety of symptoms,2 including:3

  • vasomotor symptoms such as hot flushes
  • disrupted sleep (with or without night sweats)
  • mood changes such as depression
  • vaginal dryness and dyspareunia
  • muscle and joint ache
Besides these symptoms, oestrogen deficiency can result in osteoporosis — the most prevalent disease in postmenopausal women, often resulting in poor quality of life. 4 Woman looking into camera Woman looking into camera

LIVIAL offers benefits to postmenopausal women experiencing oestrogen-deficiency symptoms1

In postmenopausal women taking LIVIAL for hormone replacement therapy (HRT), LIVIAL vs. no treatment:

  • relieved vasomotor symptoms (at 6 months from baseline, n=77) 5
  • improved vaginal atrophy (at 6 years from baseline, n=39) 6
  • maintained bone mass density (over 2 years from baseline, n=35) 7

Read about the safety and tolerability profile of LIVIAL below:

Endometrial hyperplasia and carcinoma1
Undesirable side effects1
Risk of breast cancer1,8

How to initiate or switch to LIVIAL1

Any irregular/unscheduled vaginal bleeding, either on or off HRT, should be investigated to exclude malignancy before starting LIVIAL.1

LIVIAL is indicated for:1

  • the treatment of oestrogen-deficiency symptoms in postmenopausal women, more than 1 year after menopause
  • the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

For all women, the decision to prescribe LIVIAL should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke.1

The images are for illustrative purposes only. The women shown are models who have granted permission for their image to be used

Abbreviations

GnRH = Gonadotropin-Releasing Hormone;
HRT = Hormone Replacement Therapy;
MHT = Menopausal Hormone Therapy;
MWS = Million Women Study.

Woman looking into sky

Related resource

With Women in Mind - Contraception and Menopause

Access on-demand content from our past event where we have discussed with our panel of experts - Scott McKenzie, Dr Farah Chaudhry, Dr Paula Briggs - cultural considerations in contraception and managing the woman's contraception journey to menopause.

See on-demand content

References

  1. LIVIAL Summary of Product Characteristics.
  2. Landgren M B, Helmond F A, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50(3):222-230.
  3. Santoro N, Epperson C N and Mathews S B. Menopausal symptoms and their management. Endocrionl Metab Clin North Am 2015;44(3):497-515.
  4. Ji M X, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 2015;1(1):9-13.
  5. Egarter C, Huber J et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23(1):55-62.
  6. Morris E P, Wilson P O et al. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106(9):954-959.
  7. Lippuner K, Haenggi W et al. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J Bone Miner Res 1997;12(5):806-812.
  8. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394(10204):1159-1168.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

By clicking the above links you will leave the Organon website and be taken to external websites.

GB-XLI-110008  | Date of Preparation: September 2021